Neutrophil migration across endothelium: transcellular or paracellular? ----------------------------------------------------------------------------------------------------------------Ke Zen and Charles A. Parkos EMORY UNIVERSITY
ICAM-1 controls neutrophil transendothelial migration (TEM) via both transcellular (nonjunctional) and paracellular (junctional) pathways.
E
xtravasation of blood leukocytes is critical for immune surveillance and a first step in the development of inflammation and atherosclerosis. While several events involved in neutrophil TEM, such as selectin-mediated rolling and integrin-mediated firm adhesion, are well characterized, there is controversy over the route taken by polymorphonuclear leukocytes (PMNs) as they migrate across the endothelium. As summarized in the figure, two major models for leukocyte TEM have been proposed. One involves a traditional paracellular pathway that has been the focus of the majority of transmigration studies using in vitro systems. 1 By this pathway, neutrophils migrate across the endothelial monolayer at cell-cell junctions. This model envisions a combination of localized endothelial-presented chemoattractants and adhesion molecules, such as platelet endothelial cell adhesion molecule-1 (PECAM-1), CD99, and junctional adhesion molecules, playing critical roles in driving diapedesis. The other route of migration is the transcellular pathway that involves TEM of leukocytes at nonjunctional locations, or "through" the endothelial cell. This model is supported by previous electron microscopic observations of neutrophil transmigration in in vivo models of inflammation. ICAM-1 is necessary for its function in modulating neutrophil-endothelial interactions. Although the mechanism is still not clear, ligation of endothelial ICAM-1 by LFA-1 likely results in ICAM-1-meditated signaling that leads to cytoskeleton changes and leukocyte TEM. 4 Not only did the authors find that the surface density of ICAM-1 is important in regulating transcellular migration, but they observed that the shape of endothelial cells played a role in determining the migration route of PMNs. Comparison of PMN migration across ICAM-1GFP-transfected and control endothelial monolayers revealed that endothelial cells with polygonal morphology appeared to promote nonjunctional arrest and transcellular migration. Interestingly, polygonal endothelial cells with high-density expression of ICAM-1 and VCAM-1 have been identified in locations with high predilection for atherosclerosis in both rabbit and mouse models of atherogenesis. 5 It is thus likely that these conditions (high density of ICAM-1 and polygonal endothelial cell shape) might support a high ratio of transcellular to paracellular TEM and contribute to disease pathogenesis. Another interesting point from this study was that T lymphocytes, unlike neutrophils, do not migrate via transcellular mechanisms even under conditions of increased ICAM-1 expression. Future in vitro studies are needed to determine if TEM of monocytes is similar to that observed for PMNs or T lymphocytes. -------------------------------------------------------------------------------------------------------------- 
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SDX-101, the etodolac R-enantiomer, is an anti-inflammatory drug with a cytotoxic effect on multiple myeloma cells but not on normal peripheral blood mononuclear cells.
T he antiproliferative activity of nonsteroidal anti-inflammatory drugs and their potential use as antitumor agents are under scrutiny. 1 A starting point is the demonstration that these drugs have some effects on cancer cells.
In this issue of Blood, Yasui and colleagues provide the first evidence of the cytotoxic effect of SDX-101, the R-enantiomer of etodolac, in different multiple myeloma (MM) cell lines. The authors illustrate SDX-101's antitumor activity against both drug-sensitive and -resistant MM cells and against primary patient MM cells within the bone marrow environment. It is important to bear in mind that these effects were obtained with concentrations without cytotoxicity on normal peripheral blood mononuclear cells and at clinically achievable plasma levels. Some MM cells were resistant to doxorubicin, dexamethasone, and bortezomib and were hence highly hypermutated. The cytotoxic effect is mediated via caspase-8/-9/-3 activation and apoptosis. In addition, SDX-101 induced downregulation of cyclin D1 expression in MM cells, resulting in an apoptotic population, as shown by cell-cycle analysis.
As they have previously shown that novel chemotherapeutic agents augment the cytotoxicity of dexamethasone, 2 Yasui and colleagues now demonstrate that the combination of SDX-101 plus dexamethasone is highly synergistic. It has been well established that myeloid cell leukemia-1 (Mcl-1) plays an important role in proliferation and inhibition of apoptosis, as well as in the induction of drug resistance 3 It has previously been reported that the bone marrow microenvironment plays an important role in the pathogenesis of MM. 4, 5 Yasui and colleagues demonstrate that SDX-101 ablates the growth stimulatory effect of this microenvironment on MM cells. It is interesting to note that SDX-101 lacks cyclooxygenase (COX) inhibitory activity and hence the related side effects and that it is approved for treatment of degenerative joint diseases and rheumatoid arthritis. Results as a whole provide the preclinical framework for clinical trials of SDX-101 alone or in combination with dexamethasone to improve patient outcome in MM. The study is an important contribution to MM research. ■
